Are Investors Undervaluing Zimmer Biomet ( ZBH ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ZBH Receives PMDA Approval in Japan for iTaperloc Complete and iG7
Zimmer Biomet wins early PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology.
Here's Why Zimmer Biomet ( ZBH ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Beauty Health Company Names Pedro Malha President and Chief Executive Officer - Beauty Health ( NASDAQ:SKIN )
Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth
Looking Into Zimmer Biomet Holdings Inc's Recent Short Interest - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Holdings Inc's ( NYSE:ZBH ) short interest as a percent of float has risen 13.1% since its last report. According to exchange reported data, there are now 6.57 million shares sold short, which is 3.8% of all regular shares that are available for trading.
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet ( ZBH Quick QuoteZBH - ) and EssilorLuxottica Unsponsored ADR ( ESLOY Quick QuoteESLOY - ) . But which of these two companies is the best option for those looking for undervalued stocks?
ISRG vs. ZBH: Which Robotic Surgery Stock Offers Better Upside Now?
ISRG and ZBH both push robotics forward, but valuation and Zacks Rank tilt near-term upside toward Zimmer Biomet. Which one offers a better bet?
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.
All You Need to Know About Zimmer ( ZBH ) Rating Upgrade to Buy
Zimmer (ZBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Zimmer Biomet ( ZBH ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Insider Decision: Sang Yi Offloads $124K Worth Of Zimmer Biomet Holdings Stock - Zimmer Biomet Holdings ( NYSE:ZBH )
Sang Yi, Group President at Zimmer Biomet Holdings ZBH, disclosed an insider sell on September 15, according to a recent SEC filing. What Happened: Yi's decision to sell 1,200 shares of Zimmer Biomet Holdings was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on ...
Why Zimmer Biomet ( ZBH ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZBH or ESLOY: Which Is the Better Value Stock Right Now?
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Are Investors Undervaluing Phibro Animal Health ( PAHC ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Mid-Cap Value Mutual Funds to Buy Amid Volatile Market Conditions
Amid market volatility, TGVOX, VASVX and TRMCX stand out with strong returns, low costs and exposure to growth-driven mid-cap value stocks.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Investors Undervaluing Smith & Nephew SNATS ( SNN ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Zimmer Biomet ( ZBH ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Add Zimmer Biomet Stock to Your Portfolio Now?
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet ( ZBH Quick QuoteZBH - ) and EssilorLuxottica Unsponsored ADR ( ESLOY Quick QuoteESLOY - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Stryker's Robotics and Global Gains Offset by Macro Concerns
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
Here's Why Zimmer Biomet ( ZBH ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Looking Into Zimmer Biomet Holdings's Recent Short Interest - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Holdings's ZBH short percent of float has fallen 19.29% since its last report. The company recently reported that it has 5.93 million shares sold short, which is 3.43% of all regular shares that are available for trading.
NeuroOne Q3 Revenue Jumps 105 Percent
NeuroOne Medical Technologies ( NASDAQ:NMTC ) reported fiscal third quarter 2025 earnings on August 14, 2025, with product revenue up 105% year-over-year to $1.7 million and product gross margins rising to 53.9% from 34.1% in the third quarter of fiscal year 2024.
NeuroOne ( NMTC ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Aug. 14, 2025 at 8:30 a.m. ETChief Executive Officer - David A. RosaContinue reading ...
NeuroOne Revenue Jumps 105 Percent in Q3
NeuroOne Medical Technologies ( NASDAQ:NMTC ) , a med-tech company specializing in advanced thin film electrode and ablation systems for neurological disorders, reported Q3 FY2025 results on August 14, 2025. The earnings release showcased a material improvement in profitability, with earnings per ...
Why Zimmer Biomet ( ZBH ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners.
Zimmer Biomet Flexes Strong Q2, Raises 2025 Outlook - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Q2 EPS rises 3% to $2.07, beating the $1.99 estimate; sales reaches $2.08 billion, topping the consensus. 2025 EPS guidance raises to $8.10-$8.30 vs. $7.90-$8.10 prior; revenue growth forecast narrows to 6.7%-7.7% The market's back, and these 3 income stocks are thriving.
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
Zimmer Biomet gains as Q2 earnings and revenues top estimates. full-year EPS guidance raised on strong segment growth.
Zimmer Biomet ( ZBH ) Q2 Revenue Jumps 7%
Zimmer Biomet ( NYSE:ZBH ) , an orthopedic medical technology company, reported its earnings on August 7, 2025. The company announced GAAP revenue of $2.077 billion, beating analyst estimates of $2.057 billion. Adjusted earnings per share ( EPS ) , a profitability metric that excludes certain ...
Zimmer Biomet ( ZBH ) Beats Q2 Earnings and Revenue Estimates
Zimmer (ZBH) delivered earnings and revenue surprises of +4.55% and +1.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Zimmer ( ZBH ) Q2 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Zimmer Biomet to Report Q2 Earnings: Here's What to Expect
ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.
BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter
SUNNYVALE, Calif., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provides the anticipated timing of regulatory activities seeking FDA and Japan PMDA ...
Will Canopy Growth Corporation ( CGC ) Report Negative Earnings Next Week? What You Should Know
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Zimmer Biomet ( ZBH ) to Report a Decline in Earnings: What to Look Out for
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Monogram Technologies Announces World's First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery
The Procedure Utilized Monogram's mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World's First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient
What Does the Market Think About Zimmer Biomet Holdings? - Zimmer Biomet Holdings ( NYSE:ZBH )
Zimmer Biomet Holdings's ZBH short percent of float has fallen 13.09% since its last report. The company recently reported that it has 7.34 million shares sold short, which is 4.25% of all regular shares that are available for trading.
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025
PALM BEACH GARDENS, Fla., July 25, 2025 ( GLOBE NEWSWIRE ) -- ZimVie Inc. ( Nasdaq: ZIMV ) , a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on ...
ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025 - ZimVie ( NASDAQ:ZIMV )
PALM BEACH GARDENS, Fla., July 25, 2025 ( GLOBE NEWSWIRE ) -- ZimVie Inc. ZIMV, a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July ...
P/E Ratio Insights for Zimmer Biomet Holdings - Zimmer Biomet Holdings ( NYSE:ZBH )
Looking into the current session, Zimmer Biomet Holdings Inc. ZBH shares are trading at $97.99, after a 1.52% increase. Moreover, over the past month, the stock increased by 5.16%, but in the past year, fell by 12.03%.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SONN, FCCO, MGRM on Behalf of Shareholders - Monogram Technologies ( NASDAQ:MGRM ) , First Community ( NASDAQ:FCCO )
NEW YORK, July 19, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sonnet BioTherapeutics, Inc.
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.
4 Mid-Cap Value Mutual Funds for Long-Term Gains
VASVX, TAMVX, TRVPX and FVLKX offer mid-cap value exposure with solid returns, low fees, and long-term growth potential.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAT, VBTX, MGRM on Behalf of Shareholders - Monogram Technologies ( NASDAQ:MGRM ) , Veritex Holdings ( NASDAQ:VBTX )
NEW YORK, July 16, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, MRGM, SONN on Behalf of Shareholders - Monogram Technologies ( NASDAQ:MGRM ) , WK Kellogg ( NYSE:KLG )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Monogram Technologies Inc. ( NASDAQ: MGRM )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
